

1. Hunger SP, Lu X, Devidas M, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the Children's Oncology Group. *J Clin Oncol* 2012;30:1663–1669.
2. Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. *Lancet* 2013;381:1943–1955.
3. Freed J, Kelly KM. Current approaches to the management of pediatric Hodgkin lymphoma. *Paediatr Drugs* 2010;12:85–98.
4. Reiter A. Non-Hodgkin lymphoma in children and adolescents. *Klin Padiatr* 2013;225:S87–S93.
5. Creutzig U, van den Heuvel-Eibrink MM, Gibson B, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. *Blood* 2012;120:3187–3205.
6. Rubnitz JE, Gibson B, Smith FO. Acute myeloid leukemia. *Hematol Oncol Clin North Am* 2010;24:35–63.
7. Bleyer A, Morgan S, Barr R. Proceedings of a workshop: bridging the gap in care and addressing participation in clinical trials. *Cancer* 2006;107:1656–1658.
8. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. *Lancet* 2008;371:1030–1043.
9. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. *CA Cancer J Clin* 2009;59:225–249.
10. Bhatia S, Sather HN, Heerema NA, et al. Racial and ethnic differences in survival of children with acute lymphoblastic leukemia. *Blood* 2002;100:1957–1964.
11. Kadan-Lottick NS, Ness KK, Bhatia S, et al. Survival variability by race and ethnicity in childhood acute lymphoblastic leukemia. *JAMA* 2003;290:2008–2014.
12. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. *N Engl J Med* 2006;354:166–178.
13. Pui CH, Pei D, Pappo AS, et al. Treatment outcomes in black and white children with cancer: results from the SEER database and St Jude Children's Research Hospital, 1992 through 2007. *J Clin Oncol* 2012;30:2005–2012.
14. Bhatia S, Landier W, Shangguan M, et al. Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the Children's Oncology Group. *J Clin Oncol* 2012;30:2094–2101.
15. Xie Y, Davies SM, Xiang Y, et al. Trends in leukemia incidence and survival in the United States (1973–1998). *Cancer* 2003;97:2229–2235.
16. Glaubach T, Robinson LJ, Corey SJ. Pediatric myelodysplastic syndromes: they do exist! *J Pediatr Hematol Oncol* 2014;36:1–7.
17. Bhatia S, Neglia JP. Epidemiology of childhood acute myelogenous leukemia. *J Pediatr Hematol Oncol* 1995;17:94–100.
18. Children's Oncology Group, Aplenc R, Alonzo TA, et al. Ethnicity and survival in childhood acute myeloid leukemia: a report from the Children's Oncology Group. *Blood* 2006;108:74–80.
19. Meshinchi S, Arceci RJ. Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia. *Oncologist* 2007;12:341–355.
20. Hann IM, Webb DK, Gibson BE, et al. MRC trials in childhood acute myeloid leukaemia. *Ann Hematol* 2004;83:S108–S112.
21. Kim AS, Eastmond DA, Preston RJ. Childhood acute lymphocytic leukemia and perspectives on risk assessment of early-life stage exposures. *Mutat Res* 2006;613:138–160.
22. McNally RJ, Eden TO. An infectious aetiology for childhood acute leukaemia: a review of the evidence. *Br J Haematol* 2004;127:243–263.
23. Mallol-Mesnard N, Menegaux F, Auvrignon A, et al. Vaccination and the risk of childhood acute leukaemia: the ESCALE study (SFCE). *Int J Epidemiol* 2007;36:110–116.
24. Kleinerman RA, Kaune WT, Hatch EE, et al. Are children living near high-voltage power lines at increased risk of acute lymphoblastic leukemia? *Am J Epidemiol* 2000;151:512–515.
25. Kabuto M, Nitta H, Yamamoto S, et al. Childhood leukemia and magnetic fields in Japan: a case-control study of childhood leukemia and residential power-frequency magnetic fields in Japan. *Int J Cancer* 2006;119:643–650.
26. Svendsen AL, Wehkopf T, Kaatsch P, et al. Exposure to magnetic fields and survival after diagnosis of childhood leukemia: a German cohort study. *Cancer Epidemiol Biomarkers Prev* 2007;16:1167–1171.
27. Bolufer P, Collado M, Barragan E, et al. The potential effect of gender in combination with common genetic polymorphisms of drug-metabolizing enzymes on the risk of developing acute leukemia. *Haematologica* 2007;92:308–314.
28. Ford AM, Ridge SA, Cabrera ME, et al. In utero rearrangements in the trithorax-related oncogene in infant leukaemias. *Nature* 1993;363:358–360.
29. Bateman CM, Colman SM, Chaplin T, et al. Acquisition of genome-wide copy number alterations in monozygotic twins with acute lymphoblastic leukemia. *Blood* 2010;115:3553–3558.
30. Gale KB, Ford AM, Repp R, et al. Backtracking leukemia to birth: identification of clonotypic gene fusion sequences in neonatal blood spots. *Proc Natl Acad Sci U S A* 1997;94:13950–13954.
31. Greaves MF, Maia AT, Wiemels JL, et al. Leukemia in twins: lessons in natural history. *Blood* 2003;102:2321–2333.
32. Greaves M. Infection, immune responses and the aetiology of childhood leukaemia. *Nat Rev Cancer* 2006;6:193–203.
33. Trevino LR, Yang W, French D, et al. Germline genomic variants associated with childhood acute lymphoblastic leukemia. *Nat Genet* 2009;41:1001–1005.
34. Papaemmanuil E, Hosking FJ, Vijayakrishnan J, et al. Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia. *Nat Genet* 2009;41:1006–1010.
35. Sherborne AL, Hosking FJ, Prasad RB, et al. Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk. *Nat Genet* 2010;42:492–494.
36. Perez-Andreu V, Roberts KG, Harvey RC, et al. Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. *Nat Genet* 2013;45:1494–1498.
37. Xu H, Cheng C, Devidas M, et al. ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia. *J Clin Oncol* 2012;30:751–757.
38. Shah S, Schrader KA, Waanders E, et al. A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. *Nat Genet* 2013;45:1226–1231.
39. Holmfeldt L, Wei L, Diaz-Flores E, et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. *Nat Genet* 2013;45:242–252.
40. Zwaan MC, Reinhardt D, Hitzler J, et al. Acute leukaemias in children with Down syndrome. *Pediatr Clin North Am* 2008;55:53–70.
41. Linabery AM, Blair CK, Gamis AS, et al. Congenital abnormalities and acute leukemia among children with Down syndrome: a Children's Oncology Group study. *Cancer Epidemiol Biomarkers Prev* 2008;17:2572–2577.
42. Rabin KR, Whitlock JA. Malignancy in children with trisomy 21. *Oncologist* 2009;14:164–173.
43. Arico M, Ziino O, Valsecchi MG, et al. Acute lymphoblastic leukemia and Down syndrome: presenting features and treatment outcome in the experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP). *Cancer* 2008;113:515–521.
44. Forestier E, Izraeli S, Beverloo B, et al. Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: an iBFM-SG study. *Blood* 2008;111:1575–1583.
45. Maloney KW, Carroll WL, Carroll AJ, et al. Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology Group. *Blood* 2010;116:1045–1050.
46. Bercovich D, Ganmore I, Scott LM, et al. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. *Lancet* 2008;372:1484–1492.
47. Russell LJ, Capasso M, Vater I, et al. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B cell precursor acute lymphoblastic leukemia. *Blood* 2009;114:2688–2698.
48. Mullighan CG, Collins-Underwood JR, Phillips LA, et al. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. *Nat Genet* 2009;41:1243–1246.
49. Massey GV, Zipursky A, Chang MN, et al. A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481. *Blood* 2006;107:4606–4613.
50. Ge Y, Dombkowski AA, LaFiura KM, et al. Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia. *Blood* 2006;107:1570–1581.
51. Pui CH, Campana D. New definition of remission in childhood acute lymphoblastic leukemia. *Leukemia* 2000;14:783–785.
52. Campana D. Minimal residual disease in acute lymphoblastic leukemia. *Semin Hematol* 2009;46:100–106.
53. Faham M, Zheng J, Moorhead M, et al. Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. *Blood* 2012;120:5173–5180.
54. Arceci RJ. Progress and controversies in the treatment of pediatric acute myelogenous leukemia. *Curr Opin Hematol* 2002;9:353–360.
55. Dusenbery KE, Howells WB, Arthur DC, et al. Extramedullary leukemia in children with newly diagnosed acute myeloid leukemia: a report from the Children's Cancer Group. *J Pediatr Hematol Oncol* 2003;25:760–768.
56. Pui CH, Howard SC. Current management and challenges of malignant disease in the CNS in paediatric leukaemia. *Lancet Oncol* 2008;9:257–268.
57. Swerdlow SH, Campo E, Harris NL. *WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues*. Lyon, France: WHO; 2008.
58. Holleman A, Cheok MH, den Boer ML, et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. *N Engl J Med* 2004;351:533–542.
59. Lu XY, Harris CP, Cooley L, et al. The utility of spectral karyotyping in the cytogenetic analysis of newly diagnosed pediatric acute lymphoblastic leukemia. *Leukemia* 2002;16:2222–2227.
60. Mullighan CG, Goorha S, Radtke I, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. *Nature* 2007;446:758–764.
61. Zhang J, Ding L, Holmfeldt L, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. *Nature* 2012;481:157–163.
62. Welch JS, Westervelt P, Ding L, et al. Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. *JAMA* 2011;305:1577–1584.
63. Wei G, Twomey D, Lamb J, et al. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. *Cancer Cell* 2006;10:331–342.

64. Roberts KG, Morin RD, Zhang J, et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. *Cancer Cell* 2012;22:153–166.
65. Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. *J Clin Oncol* 1996;14:18–24.
66. Hilden JM, Dinndorf PA, Meerbaum SO, et al. Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group. *Blood* 2006;108:441–451.
67. Nagayama J, Tomizawa D, Koh K, et al. Infants with acute lymphoblastic leukemia and a germline MLL gene are highly curable with use of chemotherapy alone: results from the Japan Infant Leukemia Study Group. *Blood* 2006;107:4663–4665.
68. Pieters R, Schrappe M, De Lorenzo P, et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. *Lancet* 2007;370:240–250.
69. Dreyer ZE, Dinndorf PA, Camitta B, et al. Analysis of the role of hematopoietic stem-cell transplantation in infants with acute lymphoblastic leukemia in first remission and MLL gene rearrangements: a report from the Children's Oncology Group. *J Clin Oncol* 2011;29:214–222.
70. Nachman JB, La MK, Hunger SP, et al. 2009. Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the Children's Oncology Group. *J Clin Oncol* 27:5189–5194.
71. Trueworthy R, Shuster J, Look T, et al. Ploidy of lymphoblasts is the strongest predictor of treatment outcome in B-progenitor cell acute lymphoblastic leukemia of childhood: a Pediatric Oncology Group study. *J Clin Oncol* 1992;10:606–613.
72. Heerema NA, Raimondi SC, Anderson JR, et al. Specific extra chromosomes occur in a modal number dependent pattern in pediatric acute lymphoblastic leukemia. *Genes Chromosomes Cancer* 2007;46:684–693.
73. Borowitz MJ, Devidas M, Hunger SP, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. *Blood* 2008;111:5477–5485.
74. Nachman JB, Heerema NA, Sather H, et al. Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. *Blood* 2007;110:1112–1115.
75. Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. *N Engl J Med* 2009;360:470–480.
76. Rand V, Parker H, Russell LJ, et al. Genomic characterization implicates iAMP21 as a likely primary genetic event in childhood B-cell precursor acute lymphoblastic leukemia. *Blood* 2011;117:6848–6855.
77. Chen IM, Harvey RC, Mullighan CG, et al. Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study. *Blood* 2012;119:3512–3522.
78. van der Veer A, Waanders E, Pieters R, et al. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. *Blood* 2013;122:2622–2629.
79. Rubnitz JE, Wichlan D, Devidas M, et al. Prospective analysis of TEL gene rearrangements in childhood acute lymphoblastic leukemia: a Children's Oncology Group study. *J Clin Oncol* 2008;26:2186–2191.
80. Aldrich MC, Zhang L, Wiemels JL, et al. Cytogenetics of Hispanic and White children with acute lymphoblastic leukemia in California. *Cancer Epidemiol Biomarkers Prev* 2006;15:578–581.
81. Arico M, Valsecchi MG, Camitta B, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. *N Engl J Med* 2000;342:998–1006.
82. Schultz KR, Carroll A, Heerema NA, et al. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group Study AALL0031. *Leukemia* 2014 Jul;28(7):1467–1471. Epub 2014 Jan 20.
83. Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a Children's Oncology Group study. *J Clin Oncol* 2009;27:5175–5181.
84. Foa R, Vitale A, Vignetti M, et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. *Blood* 2011;118:6521–6528.
85. Breit S, Stanulla M, Flohr T, et al. Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. *Blood* 2006;108:1151–1157.
86. Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. *Science* 2004;306:269–271.
87. Coustan-Smith E, Mullighan CG, Onciu M, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. *Lancet Oncol* 2009;10:147–156.
88. Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. *N Engl J Med* 2009;360:2730–2741.
89. Einsiedel HG, von Stankelberg A, Hartmann R, et al. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Munster Group 87. *J Clin Oncol* 2005;23:7942–7950.
90. Schrappe M, Reiter A, Riehm H. Cytoreduction and prognosis in childhood acute lymphoblastic leukemia. *J Clin Oncol* 1996;14:2403–2406.
91. Schrappe M, Hunger SP, Pui CH, et al. Outcomes after induction failure in childhood acute lymphoblastic leukemia. *N Engl J Med* 2012;366:1371–1381.
92. Schrappe M, Nachman J, Hunger S, et al. 'Educational symposium on long-term results of large prospective clinical trials for childhood acute lymphoblastic leukemia (1985–2000)'. *Leukemia* 2010;24:253–254.
93. Pui CH, Pei D, Sandlund JT, et al. Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. *Leukemia* 2010;24:371–382.
94. Tubergen DG, Gilchrist GS, O'Brien RT, et al. Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: a Children's Cancer Group report. *J Clin Oncol* 1993;11:520–526.
95. Finklestein JZ, Miller DR, Feusner J, et al. Treatment of overt isolated testicular relapse in children on therapy for acute lymphoblastic leukemia. A report from the Children's Cancer Group. *Cancer* 1994;73:219–223.
96. Nguyen K, Devidas M, Cheng SC, et al. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study. *Leukemia* 2008;22:2142–2150.
97. Freyer DR, Devidas M, La M, et al. Postrelapse survival in childhood acute lymphoblastic leukemia is independent of initial treatment intensity: a report from the Children's Oncology Group. *Blood* 2011;117:3010–3015.
98. Raetz EA, Borowitz MJ, Devidas M, et al. Reinduction platform for children with first marrow relapse of acute lymphoblastic leukemia: a Children's Oncology Group Study [corrected]. *J Clin Oncol* 2008;26:3971–3978.
99. Jeha S. New therapeutic strategies in acute lymphoblastic leukemia. *Semin Hematol* 2009;46:76–88.
100. Jeha S, Gaynon PS, Razzouk BI, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. *J Clin Oncol* 2006;24:1917–1923.
101. Hijjiya N, Gaynon P, Barry E, et al. A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia. *Leukemia* 2009;23:2259–2264.
102. Topp MS, Kufer P, Gokbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. *J Clin Oncol* 2011;29:2493–2498.
103. Topp MS, Gokbuget N, Zugmaier G, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. *Blood* 2012;120:5185–5187.
104. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. *N Engl J Med* 2013;368:1509–1518.
105. Grupp SA, Frey NV, Aplenc R. T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019) produce significant in vivo proliferation, complete responses and long-term persistence without GVHD in children and adults with relapsed, refractory ALL. *Blood* 2013;122(abstract 67).
106. Mehta PA, Davies SM. Allogeneic transplantation for childhood ALL. *Bone Marrow Transplant* 2008;41:133–139.
107. Kaspers GJ, Zwaan CM. Pediatric acute myeloid leukemia: towards high-quality cure of all patients. *Haematologica* 2007;92:1519–1532.
108. Kaspers GJ, Creutzig U. Pediatric acute myeloid leukemia: international progress and future directions. *Leukemia* 2005;19:2025–2029.
109. Pollard JA, Alonzo TA, Gerbing RB, et al. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. *Blood* 2010;115:2372–2379.
110. Canner J, Alonzo TA, Franklin J, et al. Differences in outcomes of newly diagnosed acute myeloid leukemia for adolescent/young adult and younger patients: a report from the Children's Oncology Group. *Cancer* 2013;119:4162–4169.
111. Hollink IH, Zwaan CM, Zimmermann M, et al. Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML. *Leukemia* 2009;23:262–270.
112. Ho PA, Alonzo TA, Gerbing RB, et al. Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. *Blood* 2009;113:6558–6566.
113. Buccisano F, Maurillo L, Del Principe MI, et al. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. *Blood* 2012;119:332–341.
114. Woods WG. Curing childhood acute myeloid leukemia (AML) at the half-way point: promises to keep and miles to go before we sleep. *Pediatr Blood Cancer* 2006;46:565–569.
115. Gamis AS, Alonzo TA, Perentesis JP, et al. Children's Oncology Group's 2013 blueprint for research: acute myeloid leukemia. *Pediatr Blood Cancer* 2013;60:964–971.
116. Woods WG, Neudorf S, Gold S, et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. *Blood* 2001;97:56–62.
117. Kardos G, Zwaan CM, Kaspers GJ, et al. Treatment strategy and results in children treated on three Dutch Childhood Oncology Group acute myeloid leukemia trials. *Leukemia* 2005;19:2063–2071.

118. Gamis A, Aplenc R, Alonzo T, et al. Gemtuzumab Ozogamicin (GO) in children with de novo acute myeloid leukemia (AML) improves event-free survival (EFS) by reducing relapse risk—results from the randomized phase III Children's Oncology Group (COG) trial, AAML0531. *ASH Annual Meeting* 2013;(abstract 355).
119. Horton TM, Pafi D, Plon SE, et al. A phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study. *Clin Cancer Res* 2007;13:1516–1522.
120. Widemann BC, Kim A, Fox E, et al. A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report. *Clin Cancer Res* 2012;18:6011–6022.
121. Bunin NJ, Davies SM, Aplenc R, et al. Unrelated donor bone marrow transplantation for children with acute myeloid leukemia beyond first remission or refractory to chemotherapy. *J Clin Oncol* 2008;26:4326–4332.
122. Horan JT, Alonzo TA, Lyman GH, et al. Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology Group. *J Clin Oncol* 2008;26:5797–5801.
123. Biondi A, Rovelli A, Cantu-Rajno A, et al. Acute promyelocytic leukemia in children: experience of the Italian Pediatric Hematology and Oncology Group (AIEOP). *Leukemia* 1994;8:S66–S70.
124. Ribeiro R. Update on the management of pediatric acute promyelocytic leukemia. *Clin Adv Hematol Oncol* 2006;4:263–265.
125. Zhou J, Zhang Y, Li J, et al. Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia. *Blood* 2010;115:1697–1702.
126. Juliusson G, Lazarevic V, Horstedt AS, et al. Acute myeloid leukemia in the real world: why population-based registries are needed. *Blood* 2012;119:3890–3899.
127. Dvorak CC, Agarwal R, Dahl GV, et al. Hematopoietic stem cell transplant for pediatric acute promyelocytic leukemia. *Biol Blood Marrow Transplant* 2008;14:824–830.
128. Gamis AS, Woods WG, Alonzo TA, et al. Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891. *J Clin Oncol* 2003;21:3415–3422.
129. Abildgaard L, Ellebaek E, Gustafsson G, et al. Optimal treatment intensity in children with Down syndrome and myeloid leukaemia: data from 56 children treated on NOPHO-AML protocols and a review of the literature. *Ann Hematol* 2006;85:275–280.
130. Rao A, Hills RK, Stiller C, et al. Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials. *Br J Haematol* 2006;132:576–583.
131. Aladjidi N, Auvergnon A, Leblanc T, et al. Outcome in children with relapsed acute myeloid leukemia after initial treatment with the French Leucemie Aigue Myeloide Infant (LAMEI) 89/91 protocol of the French Society of Pediatric Hematology and Immunology. *J Clin Oncol* 2003;21:4377–4385.
132. Oda M, Isoyama K, Ito E, et al. Survival after cord blood transplantation from unrelated donor as a second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leukemia. *Int J Hematol* 2009;89:374–382.
133. Meshinchi S, Leisenring WM, Carpenter PA, et al. Survival after second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leukemia. *Biol Blood Marrow Transplant* 2003;9:706–713.
134. Moore AS, Kearns PR, Knapper S, et al. Novel therapies for children with acute myeloid leukaemia. *Leukemia* 2013;27:1451–1460.
135. Millot F, Traore P, Guilhot J, et al. Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia. *Pediatrics* 2005;116:140–143.
136. Suttrop M, Eckardt L, Tauer JT, et al. Management of chronic myeloid leukemia in childhood. *Curr Hematol Malig Rep* 2012;7:116–124.
137. Loh ML. Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia. *Br J Haematol* 2011;152:677–687.
138. Hasle H. Myelodysplastic and myeloproliferative disorders in children. *Curr Opin Pediatr* 2007;19:1–8.
139. Loh ML, Sakai DS, Flotho C, et al. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. *Blood* 2009;114:1859–1863.
140. Locatelli F, Nollke P, Zecca M, et al. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. *Blood* 2005;105:410–419.
141. Matutes E, Pickl WF, Van't Veer M, et al. Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification. *Blood* 2011;117:3163–3171.
142. Shukla NN, Trippett TM. Non-Hodgkin's lymphoma in children and adolescents. *Curr Oncol Rep* 2006;8:387–394.
143. Swerdlow SH. Lymphoma classification and the tools of our trade: an introduction to the 2012 USCAP Long Course. *Mod Pathol* 2013;26:S1–S14.
144. Cairo MS, Perkins S. Non-Hodgkin's lymphoma in children. In: Bast RC Jr, Bast RC Jr, Holland JF, eds. *Holland-Frei Cancer Medicine*. Ontario: Hamilton; 2000.
145. Miller E, Metser U, Avrahami G, et al. Role of 18F-FDG PET/CT in staging and follow-up of lymphoma in pediatric and young adult patients. *J Comput Assist Tomogr* 2006;30:689–694.
146. Pinkerton R. Continuing challenges in childhood non-Hodgkin's lymphoma. *Br J Haematol* 2005;130:480–488.
147. Saha A, Robertson ES. Epstein-Barr virus-associated B-cell lymphomas: pathogenesis and clinical outcomes. *Clin Cancer Res* 2011;17:3056–3063.
148. Rezk SA, Weiss LM. Epstein-Barr virus-associated lymphoproliferative disorders. *Hum Pathol* 2007;38:1293–1304.
149. Mann G, Attarbaschi A, Steiner M, et al. Early and reliable diagnosis of non-Hodgkin lymphoma in childhood and adolescence: contribution of cytomorphology and flow cytometric immunophenotyping. *Pediatr Hematol Oncol* 2006;23:167–176.
150. Perger L, Lee EY, Shamberger RC. Management of children and adolescents with a critical airway due to compression by an anterior mediastinal mass. *J Pediatr Surg* 2008;43:1990–1997.
151. Asselin BL, Devidas M, Wang C, et al. Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404). *Blood* 2011;118:874–883.
152. Sandlund JT, Pui CH, Zhou Y, et al. Effective treatment of advanced-stage childhood lymphoblastic lymphoma without prophylactic cranial irradiation: results of St Jude NHL13 study. *Leukemia* 2009;23:1127–1130.
153. Burkhardt B, Woessmann W, Zimmermann M, et al. Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma. *J Clin Oncol* 2006;24:491–499.
154. DeAngelo DJ. Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. *Hematol Oncol Clin North Am* 2009;23:1121–1135.
155. Ferrando AA. The role of NOTCH1 signaling in T-ALL. *Hematology Am Soc Hematol Educ Program* 2009:353–361.
156. Real PJ, Ferrando AA. NOTCH inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemia. *Leukemia* 2009;23:1374–1377.
157. Attarbaschi A, Dworzak M, Steiner M, et al. Outcome of children with primary resistant or relapsed non-Hodgkin lymphoma and mature B-cell leukemia after intensive first-line treatment: a population-based analysis of the Austrian Cooperative Study Group. *Pediatr Blood Cancer* 2005;44:70–76.
158. Lombardi L, Newcomb EW, Dalla-Favera R. Pathogenesis of Burkitt lymphoma: expression of an activated c-myc oncogene causes the tumorigenic conversion of EBV-infected human B lymphoblasts. *Cell* 1987;49:161–170.
159. Fleming ID, Turk PS, Murphy SB, et al. Surgical implications of primary gastrointestinal lymphoma of childhood. *Arch Surg* 1990;125:252–256.
160. Molyneux EM, Rochford R, Griffin B, et al. Burkitt's lymphoma. *Lancet* 2012;379:1234–1244.
161. Hesselting P, Molyneux E, Kamiza S, et al. Endemic Burkitt lymphoma: a 28-day treatment schedule with cyclophosphamide and intrathecal methotrexate. *Ann Trop Paediatr* 2009;29:29–34.
162. Hesselting P, Broadhead R, Mansvelt E, et al. The 2000 Burkitt lymphoma trial in Malawi. *Pediatr Blood Cancer* 2005;44:245–250.
163. Patte C, Auperin A, Gerrard M, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. *Blood* 2007;109:2773–2780.
164. Crosswell HE, Bergsagel DJ, Yost R, et al. Successful treatment with modified CHOP-rituximab in pediatric AIDS-related advanced stage Burkitt lymphoma. *Pediatr Blood Cancer* 2008;50:883–885.
165. Meinhardt A, Burkhardt B, Zimmermann M, et al. Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia. *J Clin Oncol* 2010;28:3115–3121.
166. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. *Blood* 1994;84:1361–1392.
167. Griffin TC, Weitzman S, Weinstein H, et al. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. *Pediatr Blood Cancer* 2009;52:177–181.
168. Attias D, Hodgson D, Weitzman S. Primary mediastinal B-cell lymphoma in the pediatric patient: Can a rational approach to therapy be based on adult studies? *Pediatr Blood Cancer* 2009;52:566–570.
169. Grigg AP, Seymour JF. Graft versus Burkitt's lymphoma effect after allogeneic marrow transplantation. *Leuk Lymphoma* 2002;43:889–892.
170. Gambacorti-Passerini C, Messa C, Pogliani EM. Crizotinib in anaplastic large-cell lymphoma. *N Engl J Med* 2011;364:775–776.
171. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. *J Clin Oncol* 2012;30:2183–2189.
172. Sandlund JT, Hudson MM. Hematology: Treatment strategies for pediatric Hodgkin lymphoma. *Nat Rev Clin Oncol* 2010;7:243–244.
173. Rademaker J. Hodgkin's and non-Hodgkin's lymphomas. *Radiol Clin North Am* 2007;45:69–83.
174. Preciado MV, De Matteo E, Diez B, et al. Epstein-Barr virus (EBV) latent membrane protein (LMP) in tumor cells of Hodgkin's disease in pediatric patients. *Med Pediatr Oncol* 1995;24:1–5.

175. Schwartz CL. Prognostic factors in pediatric Hodgkin disease. *Curr Oncol Rep* 2003;5:498–504.
176. Furth C, Denecke T, Steffen I, et al. Correlative imaging strategies implementing CT, MRI, and PET for staging of childhood Hodgkin disease. *J Pediatr Hematol Oncol* 2006;28:501–512.
177. Stein H. Hodgkin lymphoma. In: Jaffe ES, Harris NL, Stein H, et al. eds. *World Health Organization Classification of Tumors: Tumors of Hematopoietic and Lymphoid Tissues*. Lyon: IARC Press; 2001:237.
178. Murphy SB, Morgan ER, Katzenstein HM, et al. Results of little or no treatment for lymphocyte-predominant Hodgkin disease in children and adolescents. *J Pediatr Hematol Oncol* 2003;25:684–687.
179. Pellegrino B, Terrier-Lacombe MJ, Oberlin O, et al. Lymphocyte-predominant Hodgkin's lymphoma in children: therapeutic abstention after initial lymph node resection—a Study of the French Society of Pediatric Oncology. *J Clin Oncol* 2003;21:2948–2952.
180. Fulbright JM, Raman S, McClellan WS, et al. Late effects of childhood leukemia therapy. *Curr Hematol Malig Rep* 2011;6:195–205.
181. Mody R, Li S, Dover DC, et al. Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. *Blood* 2008;111:5515–5523.
182. Bleyer WA. The impact of childhood cancer on the United States and the world. *CA Cancer J Clin* 1990;40:355–367.
183. Robison LL. Late effects of acute lymphoblastic leukemia therapy in patients diagnosed at 0-20 years of age. *Hematology Am Soc Hematol Educ Program* 2011:238–242.